Drug Profile
Research programme: CXCR4 antagonists - Consensus
Latest Information Update: 15 Sep 2006
Price :
$50
*
At a glance
- Originator Consensus Pharmaceuticals
- Class Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 15 Sep 2006 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 04 Feb 2003 This programme is still in active development
- 16 Jul 2001 New profile